Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06730750 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 360
- Enrollment target
- 6
- Study locations
NCT06730750: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
NCT06730750 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 360 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06730750, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 360 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG BMS-986490
Study Locations (6)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Michigan
- START Midwest - Grand Rapids
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Queensland
- Tasman Oncology Research - Southport
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2029-12-09 |
| Phase | Phase 1 |
What NCT06730750 shows while recruiting
NCT06730750 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT06730750 lists 6 locations in 6 states (California, Michigan, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06730750 about?
NCT06730750 is a clinical study titled "A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors". This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
What is the current status of trial NCT06730750?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 360 participants. The study started on 2025-02-12. Estimated completion is 2029-12-09.
What conditions does trial NCT06730750 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06730750?
The interventions under investigation include: Bevacizumab (DRUG), BMS-986490 (DRUG).
Who is sponsoring clinical trial NCT06730750?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06730750 being conducted?
This trial has 6 study locations across California, Michigan, New Jersey, Pennsylvania, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06730750's enrollment target sits among peer trials
360 20th of 144 higher than 125 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI